Castration-resistant prostate cancer: latest evidence and therapeutic implications
Medical oncologists who treat men with castration-resistant prostate cancer (CRPC) have seen an abundance of new agents approved by the United States Food and Drug Administration in the last decade for a disease that was previously difficult to treat after becoming resistant to androgen-deprivation...
Main Authors: | Daniel L. Suzman, Emmanuel S. Antonarakis |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2014-07-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758834014529176 |
Similar Items
-
Clinical Implications of Hedgehog Pathway Signaling in Prostate Cancer
by: Daniel L. Suzman, et al.
Published: (2015-09-01) -
Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications
by: Naoki Terada, et al.
Published: (2017-08-01) -
Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
by: Karim Boudadi, et al.
Published: (2016-01-01) -
Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
by: Karim Boudadi, et al.
Published: (2016-03-01) -
Darolutamide For Castration-Resistant Prostate Cancer
by: Bastos DA, et al.
Published: (2019-10-01)